Nunoi K, et al. - In this investigation, researchers have examined the impact of daily sodium intake on the estimated glomerular filtration rate (eGFR) by an SGLT2 inhibitor (SGLT2i), tofogliflozin (TOFO), in patients with type 2 diabetes (T2D). They analyzed individual-level data from 775 patients with T2D phase 3 trials involving TOFO treatment. During the 52-week TOFO therapy, adjusted changes in variables were compared according to basal daily salt intake (DSI), which was measured using the Tanaka formula on the basis of estimated daily urinary sodium excretion. Impact of basal DSI on changes in eGFR at Weeks 4 and 52 was investigated using multivariable analysis. Among all participants, 66% were men. Researchers observed that, among all the participants during Week 4, eGFR_MDRD sharply declined and gradually improved by Week 52, exhibiting a significant increase overall from baseline to Week 52. Basal DSI and HbA1c levels were individually correlated with eGFR_MDRD changes at Weeks 4 and 52 at multivariable analysis. They also observed that lower baseline HbA1c and DSI levels were significantly correlated with a greater increase in eGFR_MDRD at Week 52. The investigators concluded the correlation between the changed eGFR_MDRD through TOFO and dietary salt intake, in addition to glycemic control. They recommended that an appropriate dietary approach to therapy should be considered before treatment of patients with T2D with an SGLT2i.